To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

E. coli-derived rhBMP-2 offers similar fusion success to AIBG in posterolateral lumbar fusion

Download
Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Ace Report Cover
January 2018

E. coli-derived rhBMP-2 offers similar fusion success to AIBG in posterolateral lumbar fusion

Vol: 7| Issue: 1| Number:18| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

Efficacy of Escherichia coli-derived recombinant human bone morphogenetic protein-2 in posterolateral lumbar fusion: an open, active-controlled, randomized, multicenter trial

Spine J. 2017 Dec;17(12):1866-1874

Contributing Authors:
JH Lee HJ Kim KH Koo CK Lee KB Lee H Kim KS Suk JJ Yang JH Cho CJ Hwang J Han JS Yeom BS Chang WD Nam

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

100 patients scheduled for posterolateral fusion due to severe spinal stenosis, grade 1 spondylolisthesis, or spondylolysis were randomized to graft material of either Escherichia coli-derived recombinant human bone morphogenetic protein-2 (rhBMP-2) in a hydroxyapatite carrier or an autologous iliac crest bone graft. Patients were assessed primarily for fusion success on CT at 12 and 24 weeks. Sec...

Join the Conversation

Please Login or Join to leave comments.